Our Research
In parallel, we are developing a dedicated clinical research program and are actively recruiting patients for physician-led clinical studies designed to track outcomes, refine protocols, and help advance the field of regenerative medicine. Please contact us if you are interested in participating in one of our studies.
Intravenous Mesenchymal Stromal Cells for Severe and Critical COVID-19: Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials
- Under Peer Review: Journal of Translational Medicine - Springer Nature
- Publication date: January 29, 2026
- Authors: Dr Kirk Sanford DC, Dr Felix Porras MD, Dr Fergie Martinez MD, MSc, Dr Hugo Ramos MD, Dr Janine Zamitiz MD, MSc, Mr Carlos Green MSc, Mr Edward Ramsay MSc
Summary: This study examined high-quality clinical trials evaluating intravenous mesenchymal stromal cell therapy in adults with severe and critical COVID-19. By reviewing randomized, placebo-controlled studies, the analysis assessed short-term outcomes related to inflammation and clinical severity. The findings identified consistent reductions in key inflammatory markers and suggested a favorable trend in short-term outcomes, supporting continued investigation of MSC-based immunomodulatory approaches in critical illness.
Allogeneic Umbilical Cord Mesenchymal Stromal Cells for Knee Osteoarthritis: Systematic Review and Meta-Analysis of Controlled Injection Trials
- Under Peer Review: Journal of Translational Medicine - Springer Nature
- Publication date: January 30, 2026
- Authors: Dr Kirk Sanford DC, Dr Felix Porras MD, Dr Fergie Martinez MD, MSc, Dr Hugo Ramos MD, Dr Janine Zamitiz MD, MSc, Mr Carlos Green MSc, Mr Edward Ramsay MSc
Summary: This study reviewed controlled clinical trials evaluating intra-articular umbilical cord–derived mesenchymal stromal cell (MSC) injections for knee osteoarthritis. The analysis focused on longer-term pain outcomes and compared MSC injections with commonly used standard therapies. Across included studies, results showed a consistent direction of benefit at 12 months, supporting further clinical evaluation of MSC-based injection therapies for osteoarthritis.
